Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eur J Med Chem ; 156: 180-189, 2018 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-30006163

RESUMEN

The broad substrate capacity of the intestinal oligopeptide transporter, PepT1, has made it a key target of research into drug delivery. Whilst the substrate capacity of this transporter is broad, studies have largely been limited to small peptides and peptide-like drugs. Here, we demonstrate for the first time that a diverse range of drugs can be targeted towards transport by PepT1 using a hydrolysis resistant carrier. Eleven prodrugs were synthesized by conjugating modified dipeptides containing a thioamide bond to the approved drugs ibuprofen, gabapentin, propofol, aspirin, acyclovir, nabumetone, atenolol, zanamivir, baclofen and mycophenolate. Except for the aspirin and acyclovir prodrugs, which were unstable in the assay conditions and were not further studied, the prodrugs were tested for affinity and transport by PepT1 expressed in Xenopus laevis oocytes: binding affinities ranged from approximately 0.1 to 2 mM. Compounds which showed robust transport in an oocyte trans-stimulation assay were then tested for transcellular transport in Caco-2 cell monolayers: all five tested prodrugs showed significant PepT1-mediated transcellular uptake. Finally, the ibuprofen and propofol prodrugs were tested for absorption in rats: following oral dosing the intact prodrugs and free ibuprofen were measured in the plasma. This provides proof-of-concept for the idea of targeting poorly bioavailable drugs towards PepT1 transport as a general means of improving oral permeability.


Asunto(s)
Dipéptidos/metabolismo , Portadores de Fármacos/metabolismo , Sistemas de Liberación de Medicamentos , Mucosa Intestinal/metabolismo , Transportador de Péptidos 1/metabolismo , Profármacos/metabolismo , Tioamidas/metabolismo , Animales , Células CACO-2 , Dipéptidos/química , Portadores de Fármacos/química , Humanos , Absorción Intestinal , Masculino , Profármacos/química , Profármacos/farmacocinética , Ratas , Ratas Sprague-Dawley , Tioamidas/química , Xenopus laevis
2.
Org Biomol Chem ; 13(11): 3331-40, 2015 Mar 21.
Artículo en Inglés | MEDLINE | ID: mdl-25647730

RESUMEN

An efficient synthetic approach to the core structure of the manzamine alkaloids is reported, particularly in relation to incorporating a one-carbon unit in ring B from which the aldehyde in ircinal A or the beta-carboline unit in manzamine A could potentially be generated. The key steps involve a Johnson-Claisen rearrangement, enolate alkylation, dithiane alkylation and a stereoselective intramolecular dipolar cycloaddition of an azomethine ylide, which provided the desired tricyclic ABC core structure.


Asunto(s)
Carbazoles/síntesis química , Carbazoles/química , Cristalografía por Rayos X , Modelos Moleculares , Estructura Molecular
3.
PLoS One ; 9(6): e98056, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24892871

RESUMEN

Motility of the protozoan parasite Toxoplasma gondii plays an important role in the parasite's life cycle and virulence within animal and human hosts. Motility is driven by a myosin motor complex that is highly conserved across the Phylum Apicomplexa. Two key components of this complex are the class XIV unconventional myosin, TgMyoA, and its associated light chain, TgMLC1. We previously showed that treatment of parasites with a small-molecule inhibitor of T. gondii invasion and motility, tachypleginA, induces an electrophoretic mobility shift of TgMLC1 that is associated with decreased myosin motor activity. However, the direct target(s) of tachypleginA and the molecular basis of the compound-induced TgMLC1 modification were unknown. We show here by "click" chemistry labelling that TgMLC1 is a direct and covalent target of an alkyne-derivatized analogue of tachypleginA. We also show that this analogue can covalently bind to model thiol substrates. The electrophoretic mobility shift induced by another structural analogue, tachypleginA-2, was associated with the formation of a 225.118 Da adduct on S57 and/or C58, and treatment with deuterated tachypleginA-2 confirmed that the adduct was derived from the compound itself. Recombinant TgMLC1 containing a C58S mutation (but not S57A) was refractory to click labelling and no longer exhibited a mobility shift in response to compound treatment, identifying C58 as the site of compound binding on TgMLC1. Finally, a knock-in parasite line expressing the C58S mutation showed decreased sensitivity to compound treatment in a quantitative 3D motility assay. These data strongly support a model in which tachypleginA and its analogues inhibit the motility of T. gondii by binding directly and covalently to C58 of TgMLC1, thereby causing a decrease in the activity of the parasite's myosin motor.


Asunto(s)
Antiparasitarios/farmacología , Compuestos de Bencilideno/farmacología , Movimiento Celular/efectos de los fármacos , Cadenas Ligeras de Miosina/antagonistas & inhibidores , Parásitos/fisiología , Piperidonas/farmacología , Bibliotecas de Moléculas Pequeñas/farmacología , Toxoplasma/fisiología , Secuencia de Aminoácidos , Animales , Antiparasitarios/química , Compuestos de Bencilideno/química , Técnicas de Sustitución del Gen , Humanos , Masculino , Datos de Secuencia Molecular , Peso Molecular , Mutación , Cadenas Ligeras de Miosina/química , Cadenas Ligeras de Miosina/metabolismo , Parásitos/efectos de los fármacos , Pruebas de Sensibilidad Parasitaria , Péptidos/química , Piperidonas/química , Proteínas Recombinantes/química , Células Sf9 , Bibliotecas de Moléculas Pequeñas/química , Toxoplasma/efectos de los fármacos
4.
Org Biomol Chem ; 11(29): 4891-8, 2013 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-23779132

RESUMEN

3-(4-Chlorophenyl)-4-substituted pyrazole derivatives were synthesised and tested for their in vitro antifungal activity. Some compounds showed very good antifungal activity against four pathogenic strains of fungi. The same compounds exhibited an interesting activity against the tested strain of Mycobacterium tuberculosis H37Rv. The results suggest that 1,3,4-oxadiazoles and 5-pyrazolinones bearing a core pyrazole scaffold may be promising antifungal and antitubercular agents.


Asunto(s)
Antifúngicos/farmacología , Aspergillus/efectos de los fármacos , Candida/efectos de los fármacos , Cryptococcus neoformans/efectos de los fármacos , Mycobacterium tuberculosis/efectos de los fármacos , Pirazoles/farmacología , Antifúngicos/síntesis química , Antifúngicos/química , Relación Dosis-Respuesta a Droga , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Pirazoles/síntesis química , Pirazoles/química , Relación Estructura-Actividad
5.
Bioorg Med Chem Lett ; 22(15): 5129-33, 2012 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-22695129

RESUMEN

As a part of our research to develop novel antitubercular and antimicrobial agents, a series of 3-(4-chlorophenyl)-4-substituted pyrazoles have been synthesised. These compounds were tested for antitubercular activity in vitro against Mycobacterium tuberculosis H37Rv strain using the BACTEC 460 radiometric system, antifungal activity against a pathogenic strain of fungi and antibacterial activity against gram-positive and gram-negative organisms. Among them tested, many compounds showed good to excellent antimicrobial and antitubercular activity. The results suggest that hydrazones, 2-azetidinones and 4-thiazolidinones bearing a core pyrazole scaffold would be potent antimicrobial and antitubercular agents.


Asunto(s)
Antiinfecciosos/síntesis química , Antituberculosos/síntesis química , Pirazoles/química , Antiinfecciosos/química , Antiinfecciosos/farmacología , Antituberculosos/química , Antituberculosos/farmacología , Hongos/efectos de los fármacos , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Mycobacterium tuberculosis/efectos de los fármacos , Pirazoles/síntesis química , Pirazoles/farmacología , Relación Estructura-Actividad
6.
Org Biomol Chem ; 6(8): 1410-5, 2008 Apr 21.
Artículo en Inglés | MEDLINE | ID: mdl-18385847

RESUMEN

Treatment of N-alkyl-oxazolidin-2-ones with Grignard reagents gives tertiary carboxylic amide products. Various substituted oxazolidinones can be used as illustrated with phenyl, benzyl or isopropyl groups on the 4-position, and methyl, benzyl or p-methoxybenzyl groups on the 3-position (the nitrogen atom). A selection of Grignard reagents were successful, including allyl, benzyl, alkyl and phenyl magnesium halides. The organomagnesium species attacks the carbonyl group and promotes ring-opening of the oxazolidinone. The product tertiary amides are useful substrates for stereoselective transformations and were applied to a highly selective enolate alkylation and to a ring-closing metathesis reaction to a six-membered lactam and hence a formal synthesis of the alkaloids (-)-coniine and (+)-stenusine.


Asunto(s)
Amidas/síntesis química , Ácidos Carboxílicos/síntesis química , Compuestos Organometálicos/química , Oxazolidinonas/química , Amidas/química , Ácidos Carboxílicos/química , Estructura Molecular , Estereoisomerismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...